1st Quarter - Report

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC for BOEHRINGER INGELHEIM USA CORPORATION

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$1,420,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2023 $1,420,000 Replaced
1st Quarter - Amendment May 5, 2023 $1,440,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act

LobbyistCovered position, as disclosed
KATHARINE TROLLER BOND —
JULIAN MALASI —
SARAH ELIZABETH NORDSTROM —
MARY BRIDGET WALSH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act

LobbyistCovered position, as disclosed
KATHARINE TROLLER BOND —
JULIAN MALASI —
SARAH ELIZABETH NORDSTROM —
MARY BRIDGET WALSH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Animals ANI

Issues related to Animal Health Issues related to Veterinary Telehealth Issues related to One Health Issues Related to Compounding Animal Drugs from Bulk Substances Animal Drug User Fee Amendment of 2023 (H.R. 1418)

LobbyistCovered position, as disclosed
SCOTT BENNETT —
BILL DAVIS —
MARY BRIDGET WALSH —

Contacted: Agriculture, Dept of (USDA); SENATE; Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1418 (118th)

Trade (domestic/foreign) TRD

Prescription drug manufacturing and supply chains

LobbyistCovered position, as disclosed
KATHARINE TROLLER BOND —
BILL DAVIS —
JULIAN MALASI —
SARAH ELIZABETH NORDSTROM —
MARY BRIDGET WALSH —

Contacted: SENATE; Agriculture, Dept of (USDA); HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Issues related to FY2024 Appropriations

LobbyistCovered position, as disclosed
SCOTT BENNETT —
KATHARINE TROLLER BOND —
BILL DAVIS —
JULIAN MALASI —
SARAH ELIZABETH NORDSTROM —
MARY BRIDGET WALSH —

Contacted: HOUSE OF REPRESENTATIVES; Agriculture, Dept of (USDA); SENATE

Defense DEF

Issues related to National Defense Authorization Act

LobbyistCovered position, as disclosed
SCOTT BENNETT —
BILL DAVIS —
MARY BRIDGET WALSH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.